Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

智通财经APP获悉，百时美施贵宝 (BMY.US)宣布，欧盟委员会 (EC)已批准其重磅PD-1抑制剂Opdivo (nivolumab)与CTLA-4靶向抗体Yervoy (ipilimumab)联用，一线治疗不可切除或晚期肝细胞癌 (HCC)成人患者。据悉，美国FDA已接受Opdivo联合Yervoy治疗同一患者群体的补充生物制品许可申请，预计在今年4月21日之前完成审评。

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...

II) cyclophosphamide or biologics such as immunoglobulins (intravenous or s.c.), plasmapheresis, anti-type I interferon receptor biologic agents, anti-CD40 agents, CTLA4-Fc Ig or B-cell activating ...

招商国际此前研报指出，公司重磅产品CS5001 (ROR1 ADC)是目前已知首个在实体瘤和淋巴瘤中均观察到临床疗效的ROR1 ADC，其临床开发进展位于全球前二。用于治疗多种实体瘤的管线2.0重磅产品CS2009已启动全球多中心临床试验，并率先在澳大利亚递交临床试验申请，未来将陆续扩展至中国及美国。

The Witcher season 4 is on its way and it'll mark a huge new chapter in the Netflix show's saga. This time, we have a whole new Geralt of Rivia joining the fray as Liam Hemsworth becomes the White ...

（原标题：基石药业：PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期临床试验完成首例患者给药） 人民财讯3月4日电，基石药业今日 ...

金吾财讯 | 基石药业 (02616)公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。 该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动创新肿瘤免疫疗法的发展。

（原标题：基石药业-B(02616)：PD-1/VEGF/CTLA-4三特异性抗体CS2009全球多中心I期临床试验顺利完成首例患者给药） 智通财经APP讯 ...

（原标题：基石药业-B(02616.HK)：PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期临床试验完成首例患者给药） 格隆汇3月4日丨基石药业-B ...

CTLA4-Ig fusion protein (abatacept) has been shown to contribute to macrophage shift from M1 to M2 [3]. Objectives: We aimed to investigate the effects of abatacept to induce the polarization from the ...